Gaithersburg, Maryland-based Altimmune announced that the U.S. Food and Drug Administration cleared a Phase II clinical trial for the biopharmaceutical company’s investigational obesity-treating drug pemvidutide.
https://www.pharmalive.com/wp-content/uploads/2022/01/Potential-New-Obesity-Drug-Heads-to-Phase-II-Trials-BioSpace-1-31-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-01-31 16:44:002022-01-31 16:48:28Potential New Obesity Drug Heads to Phase II Trials